CA-MAWI-DNA-TECHNOLOGIES
10.5.2022 15:02:14 CEST | Business Wire | Press release
Mawi DNA Technologies (Mawi), a medical device company focusing on the development of innovative technologies for biosampling, has launched the NextSWAB™, a 100% medical-grade plastic swab designed and manufactured in the US. Mawi launched this new product in response to the COVID-19 swab shortage. It is designed for high efficiency collection without the possibility of contamination from glue or fibers used in flock and cotton swabs that may inhibit PCR based assays. NextSWAB™ is currently optimized for nasal sample collection with validation for other sample types ongoing.
“The NextSWAB™ sterile sampling applicator is six inches in length with a unique head design positioned at the distal end,” said Dr. Bassam El-Fahmawi, CEO of Mawi. “The swab head has two channels separated by a septum that retains the collected nasal material which can then be released into the transport media with a gentle shake. The flexible head fits into crevices with ease and effectiveness. It enables anterior nasal sample collection with minimal user discomfort sufficient for a meaningful result,” Dr. El-Fahmawi added.
The NextSWAB™ is compatible with many sample transport tubes making it ideal for multiple swab sample pooling in a single tube. However, to achieve optimal results, it is most effective when used in conjunction with Mawi’s iSWAB-Microbiome-EL sample collection technology which allows users to skip the RNA extraction step in COVID-19 molecular tests. A second nasal sample can be added to the same tube creating a more concentrated sample to improve overall reliability of the test. The NextSWAB™ comes ready for use and does not require any preparation for specimen collection.
“Our NextSWAB™ fully releases its contents into the sample transport media removing the need for the swab to be transported with the sample,” Dr. El-Fahmawi pointed out. “A fully concentrated liquid sample can then be quickly processed with robotic liquid handling systems or any laboratory workflow. During initial R&D testing, the unique and patent pending head design has shown higher collection efficiency for nasal (mid-turbinate and anterior nares) samples than flocked swabs,” he said.
With demand for COVID-19 sample collection swabs, the supply chain line for the NextSWAB™ is reliable and stable thanks to the plastic molded construction and USA based manufacturing. For more information on the NextSWAB™, visit www.mawidna.com .
About Mawi DNA Technologies
Mawi DNA Technologies, founded in 2013, has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Mawi’s mission is to uphold sample integrity from anywhere in the world at room temperature, enabling true sample diversity across any geography or population segment. At Mawi, The Future of Biosampling is Here™. For more information, visit http://www.mawidna.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005587/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis16.3.2026 11:53:00 CET | Press release
Almirall announces positive, top-line results from Phase 3 ADorable-1 trialADorable-1 met co-primary efficacy endpoints, with 63% of paediatric patients achieving meaningful skin improvement (EASI-75) and 44% reaching clear or almost clear skin (IGA 0,1) at week 16.Key secondary endpoints showed significant itch relief (Pruritus NRS ≥4 point improvement), reduced overall disease severity (EASI-90) and improved quality of life (CDLQI ≥6-Point Improvement) in children and adolescents with moderate-to-severe atopic dermatitis treated with lebrikizumab.Skin conditions can have a profound physical and emotional impact on people’s lives1, and Atopic Dermatitis (AD) peaks in childhood – with around 60% of cases appearing within the first year of life2. Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line results from the pivotal Phase 3 ADorable-1 trial evaluating efficacy and safety of lebrikizumab for children and adoles
Experian Marks a Breakthrough in Consumer AI with the Next Evolution of Its Virtual Assistant16.3.2026 11:00:00 CET | Press release
Smarter, more adaptive assistant advances personalized, conversational financial guidance powered by trusted data Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™, a significant advancement in its Consumer First AI strategy that expands personalized, conversational financial guidance to millions of consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316538160/en/ Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™. “This next generation of EVA reflects the direction of our consumer AI strategy,” said Debbie Hsu, Executive Vice President of Product, Experian Consumer Services. “We are bringing together conversational AI, personalization, and our trusted data foundation to deliver guidance that is intuitive, relevant, and actionable. Our focus is on helping consumers make smarter financial decisions in ways that feel simple and empowering.” Built to scal
Triton Partners Successfully Closes Fund 6 at €5.5 Billion Target16.3.2026 08:00:00 CET | Press release
Triton Partners today announces the successful close of its sixth flagship mid-market fund (“T6” or “the Fund”) on target at €5.5 billion, the largest fund to date for Triton. The Fund has raised capital from new and existing investors globally, underscoring the continued confidence of Limited Partners in Triton’s European mid-market strategy and the Firm’s ability to build better businesses. Triton’s Mid-Market buyout (TMM) strategy focuses on its core sectors of industrial technology, business services and healthcare. As a responsible owner of choice, T6 will invest where its market and investment insights provide an edge, positioning the firm to capitalise on attractive opportunities, supported by the Accelerator Unit, Europe’s largest value creation team. T6 seeks to maintain the strong performance of previous funds, all having achieved top quartile returns. Reflecting this consistent track record, Triton was recently named as one of three European managers in the HEC global univer
Syngenta deepens research capabilities with QuantumBasel partnership16.3.2026 08:00:00 CET | Press release
At the World Agri-Tech Innovation Summit, Syngenta, a global leader in agricultural innovation, today announced it is exploring how quantum computing can help farmers meet the growing demands of food production in a changing climate. The company has partnered with QuantumBasel, Switzerland's first commercial quantum computing hub, to apply quantum technologies to agricultural research and development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316646014/en/ Ion trap, which uses electromagnetic fields to confine and control ions for use as quantum bits (qubits). Farmers worldwide face mounting pressure to produce more food sustainably amid unpredictable weather and evolving pest and disease challenges. Meeting these demands requires new scientific approaches that go beyond what classical computing can deliver, particularly when it comes to understanding the complex molecular and biological systems that underpin crop sc
NTT DATA Launches GCC Innovation Acceleration Program to Support Innovation Creation by Global Companies16.3.2026 04:30:00 CET | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the launch of its GCC Innovation Acceleration Program. This is designed to support global companies rapidly establishing and scaling their strategic offshore hubs in India, including Global Capability Centers (GCC) and other innovation and delivery hubs. Launched in October 2025, the program aims to support more than 50 companies over the next three years. The demand for highly skilled IT personnel has expanded globally, and as a result, companies are increasingly using overseas bases to meet innovation needs. NTT DATA identified India as a stand-out market to launch the GCC Innovation Acceleration Program because of its abundance of talent and strong technical capabilities. India’s Global Capability Center ecosystem, delivering IT services and back-office functions to multinationals, is poised for strong growth of nearly 70%, targeting $110 billion in 2030 from the current $65 billion, according
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom